Glybera is a drug capable of curing a rare genetic disease caused by lipoprotein lipase deficiency (LPLD) that affects the pancreas. The drug alters the genetic burden of the individual and completely cures the disease and was created by the UniQure laboratory.
Treatment of lipoprotein lipase deficiency.
The price of Glybera is around 3 million reais and should start trading from 2013 in Europe.
Glyebera is well tolerated and does not cause unpleasant side effects.
Unique series of small injections into the leg, administered by doctors duly trained in centers of excellence, with experience in the treatment of this disease to ensure the safety of this new treatment.